Insilico Medicine
AI-powered drug discovery platform that identified a novel target (TNIK) for idiopathic pulmonary fibrosis and advanced a drug candidate from target identification to Phase 1 clinical trials in under 30 months — a process that traditionally takes 4-6 years. Phase 2a results published in Nature Medicine.
AI-powered drug discovery platform that identified a novel target (TNIK) for idiopathic pulmonary fibrosis and advanced a drug candidate from target identification to Phase 1 clinical trials in under 30 months — a process that traditionally takes 4-6 years. Phase 2a results published in Nature Medicine.
Key Capabilities
This vendor provides AI-powered solutions for healthcare and medical operations. Detailed case studies and implementation examples are available on their website.
Use Cases:
Industries & Tech:
Is this your company?
Claim your vendor profile to update your description, add case studies, and get priority placement.
Claim your profileSponsored
